2024 Team

Salmon xenograft

Salmon derived xenograft osteoconductive biomaterial for medical and dental applications

Osteogenic techniques have been a challenge for the medical and dental community in the fields of traumatology, neurosurgery, ETN, oral surgery, periodontics and dental implantology, among others. Important advances have been made in the development of osteogenic/osteoconductive biomaterials. Several solutions have been developed considering different origins. Bovine, porcine, synthetic, and human derived biomaterials are commercially available in the market. Nonetheless in many countries bone reconstruction solutions remain difficult to access because of the high cost of the biomaterials or the large amount needed in some cases. Depending on its origin, synthetic biomaterials have poor biologic performance. While bone reconstruction experiments an ever- growing demand, the biomaterials needed for it are expensive and face various religious and cultural limitations that limit an adequate access to bone reconstructive techniques throughout the world.

The physical, chemical, and in vitro properties of the salmon derived hydroxyapatite have been studied by us as well as its in vivo performance. Results have been encouraging enough to consider that we are in presence of a new osteoconductive/osteogenic biomaterial that could be produced at a competitive cost, with similar outcome as the commercially available products.

We have provisionally patented a collagen enriched hydroxyapatite derived from salmon bone (Salmoss©) which, among other characteristics has a low production cost, favors circular economy and does not face the current cultural and religious limitations of the products available in the market.

Team application materials

Team Lead
Francisco Muñoz Thomson


Lead Mentors